This post has been archived and contains information that may be out of date.
Prescribers are now required to offer naloxone hydrochloride, or another drug approved by the Food and Drug Administration, to patients who experience certain conditions related to opioid depression. The Medical Board of California has released frequently asked questions to assist providers in implementing the new requirements, which took effect Jan. 1.